SAFER-ROP: Updated protocol for anti-VEGF injections for retinopathy of prematurity

Kinley D. Beck, Effie Z. Rahman, Anna Ells, Kamiar Mireskandari, Audina M. Berrocal, C. Armitage Harper

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


BACKGROUND AND OBJECTIVE: To describe a safe and dependable protocol for intravitreal injections for the treatment of retinopathy of prematurity (ROP). MATERIALS AND METHODS: SAFER is an acronym used to describe the injection protocol and includes (S)hort needle (4-mm length), (A)ntiseptic/ antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser). RESULTS: No cases of cataract formation, endophthalmitis, or vitreous hemorrhage using this technique were reported in a recent retrospective chart review. CONCLUSION: This protocol is a safe way to inject anti-vascular endothelial growth factor and to monitor ROP progression following injection.

Original languageEnglish (US)
Pages (from-to)402-406
Number of pages5
JournalOphthalmic Surgery Lasers and Imaging Retina
Issue number7
StatePublished - Jul 2020

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology


Dive into the research topics of 'SAFER-ROP: Updated protocol for anti-VEGF injections for retinopathy of prematurity'. Together they form a unique fingerprint.

Cite this